POPULARITY
41 episodes with endpoints
10 episodes with endpoints
4 episodes with endpoints
3 episodes with endpoints
4 episodes with endpoints
4 episodes with endpoints
3 episodes with endpoints
4 episodes with endpoints
3 episodes with endpoints
On this episode, Daphne Zohar, John Maraganore, Josh Schimmer, Eric Schmidt and Sam Fazeli are joined by Endpoints' Zach Brennan for a discussion on the election results and what we can expect with a Trump administration, including the negatives/risks for the biotech industry as well as the positives and potential opportunities. The hosts also cover other news from the week including Moderna's Q3 earnings and the company's CEO Bancel stepping down as sales chief, as well as BioNTech's Q3 earnings and the potential softening of vaccine pricing. The group recapped the ASH conference and readouts including Arcellx's early data and related stock movement. The discussion turns to ObesityWeek highlights including data from AstraZeneca, Vertex, Zealand and Novo Nordisk. Other topics covered this week include Sarepta's SRP-5051 discontinuation, the death of gene editing and the impact to the fledgling field. This episode aired on November 8, 2024.
Today on Endpoints, Dr. Danielle Boyce joins us to explore how data science is transforming our understanding of ALS and why the ALS Research Collaborative (ARC) Study presents an exciting opportunity for research. As ALS TDI’s Principal Investigator for Real-World Evidence, Dr. Boyce brings extensive expertise in analyzing big data to uncover key insights about ALS. Her work focuses on harnessing the vast amount of information collected through ALS TDI’s ARC Study, turning data into discoveries that could drive ALS research forward.Support the show: https://www.als.net/donate/See omnystudio.com/listener for privacy information.
Can a misconfigured prompt spark a massive data breach?On this episode of Your AI Injection, host Deep Dhillon and Keith Hoodlet, Director of AI/ML and Application Security from Trail of Bits reveal the critical vulnerabilities hiding in your AI chat systems. Keith explains how RAG systems and other API endpoints, if not rigorously secured, can create unintended data portals, allowing hackers to extract everything from HR records to confidential strategic documents. The two navigate the complexities of prompt injection vulnerabilities, dynamic adversarial testing, and the balancing act between rapid innovation and robust security. As they discuss the human and technical factors that contribute to these risks, Deep and Keith challenge the industry to view security not as an afterthought, but as an integral feature of every AI-driven product. Tune in for a deep dive into safeguarding your digital future!Learn more about Keith here: https://www.linkedin.com/in/securingdev/and Trail of Bits here: https://www.trailofbits.com/Check out some of our related podcast episodes: Your Code Base Is Already Gen AI—Now What? with Matt Van Itallie of SemaWhy Generative AI Could Make Programming Languages Obsolete with Austin Vance of FocusedExploring Artificial General Intelligence: Intent, Intellect, and Innovation with Lucas Hendrich of the Forte Group
25 years ago, Steven Ascher and Jeanne Jordan began filming a documentary about a new, one-year-old organization and the family that founded it. That organization was called the ALS Therapy Development Foundation, and its mission was to find treatments for ALS. It was started by Jamie Heywood, whose brother Stephen had been diagnosed with the disease at the age of 29. The film they made, So Much So Fast, came out in 2006. It received critical acclaim and was screened at the Sundance Film Festival. It documents five years in the lives of the Heywood family as they dealt with Stephen’s progressing disease while simultaneously building what would eventually become ALS TDI, the world’s most comprehensive drug discovery lab dedicated solely to ALS. Today, on Endpoints, Steven and Jeanne join us to talk about what it was like during the earliest days of ALS TDI, what it's been like watching the organization evolve, and how their own story helped inspire the film. Support the show: https://www.als.net/donate/See omnystudio.com/listener for privacy information.
Drs. Komrokji and Kuykendall review the evolution of clinical trial endpoints in myelofibrosis studies. They discuss traditional measures of disease control, such as spleen volume reduction and hematologic response, as well as expanded endpoints that reflect the biological and symptomatic aspects of myelofibrosis.
In this episode, Meg Ashby, a senior cloud security engineer shares how her team tackled AWS's centralized VPC interface endpoints, a design often seen as an anti-pattern. She explains how they turned this unconventional approach into a cost-efficient and scalable solution, all while maintaining granular controls and network visibility. She shares why centralized VPC endpoints are considered an AWS anti-pattern, how to implement granular IAM controls in a centralized model and the challenges of monitoring and detecting VPC endpoint traffic. Guest Socials: Meg's Linkedin Podcast Twitter - @CloudSecPod If you want to watch videos of this LIVE STREAMED episode and past episodes - Check out our other Cloud Security Social Channels: - Cloud Security Podcast- Youtube - Cloud Security Newsletter - Cloud Security BootCamp Questions asked: (00:00) Introduction (02:48) A bit about Meg Ashby (03:44) What is VPC interface endpoints? (05:26) Egress and Ingress for Private Networks (08:21) Reason for using VPC endpoints (14:22) Limitations when using centralised endpoint VPCs (19:01) Marrying VPC endpoint and IAM policy (21:34) VPC endpoint specific conditions (27:52) Is this solution for everyone? (38:16) Does VPC endpoint have logging? (41:24) Improvements for the next phase Thank you to our episode sponsor Wiz. Cloud Security Podcast listeners can also get a free cloud security health scan by going to wiz.io/csp
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The FDA's accelerated approval pathway, established in 1992, has allowed over 200 new drugs to come to market based on surrogate endpoints. While many products have later received full FDA approval, recent withdrawals like Pfizer's Oxbryta and Takeda's Exkivity have raised concerns about the risks of this pathway. Despite some high-profile failures, the program has a strong track record, with over half of accelerated approvals converting to full approval. The pathway has been used primarily for cancer treatments but is now expanding to other disease areas like neurological and rare diseases. Recent failures of confirmatory trials for drugs like Sarepta's Elevidys have prompted experts to call for tighter timelines and better biomarkers for surrogate endpoints in order to improve the program. The future of the accelerated approval pathway is under scrutiny, with questions arising about how often it should be used and what areas it should focus on next.AbbVie's Tavapadon showed improvement in motor and daily living complications in a Phase III trial, following the failure of another key cerevel asset, Emraclidine. Relmada Therapeutics is considering strategic alternatives, including a potential sale, after halting two Phase III trials for a major depressive disorder drug. Other news includes BioAge discontinuing a Phase II obesity study, Merck's promising anti-ROR1 ADC data for lymphoma treatment, and Novo and Catalent's $16.5 billion deal receiving EU approval. Additionally, Vertex and Beam report advances in SCD cell and gene therapies, while evidence grows for the potential of GLP-1s in Alzheimer's disease.Recent studies have shown that GLP-1 receptor agonists, commonly used for weight loss and diabetes, may have potential in treating Alzheimer's disease. Phase III results from Novo Nordisk are expected next year. Additionally, amylin analogs are emerging as a potential alternative or complement to GLP-1 receptor agonists for weight loss with a cleaner tolerability profile. Other news includes a weight loss victory claimed by Lilly over Novo in a head-to-head study, FDA action alerts, and promising cancer therapies from companies like AstraZeneca and Merus. The FDA is also investigating the safety of Bluebird's gene therapy Skysona for hematologic malignancies. Applied Therapeutics recently faced a crash after FDA rejection of a rare disease drug. Overall, the potential of GLP-1s in Alzheimer's disease and the emergence of amylin analogs in weight loss are significant developments in the biopharma industry.
We need more – likely many more – effective treatments to end ALS. Progress in ALS research has been too slow for too long but, in 2024, we're witnessing significant advances and a new pace of progress. The past few years have see more treatments for ALS in clinical trials than ever before. Still, most drugs that reach trial fail, in any disease. However, the more experimental treatments that make it to trials – with good preclinical evidence to support them – the more likely there are to be successes. Recently, we have even seen approvals for new ALS treatments, such as tofersen, a genetic treatment developed by Biogen for SOD1-related ALS, sold under the brand name Qalsody. Dr. Stephanie Fradette was one of the people behind milestone. As the VP Head of Neuromuscular Development at Biogen, she oversees the company's research and development of treatments for ALS and related diseases. Today, on Endpoints, Dr. Fradette joins us to talk about the current state of ALS research - the biggest challenges facing researchers, the developments that give her hope for the future, and how the ALS research community could better serve people with the disease.Support the show: https://www.als.net/donate/See omnystudio.com/listener for privacy information.
Maddie Regis speaks with Tom Bowyer, Director of Security at Automox, about the intersection of IT and cybersecurity. Tom shares his career journey, the importance of collaboration between IT and security teams, and insights into SOC compliance reports. He emphasizes the need for transparency, experimentation, and proactive problem-solving in enhancing cybersecurity.
In 1999, Stephen Heywood, who was 29 years old at the time, was diagnosed with ALS. His family was devastated when they learned that there were no treatments that could slow or stop his disease. His brother Jamie decided that he had to do something about it, founding the organization that would eventually become ALS TDI – the world's first nonprofit biotech – in the basement of his parents' Newton, MA home. The first hire Jamie made as he worked to get this new organization off the ground was Rob Bonazoli. In those days, Rob was responsible for, in his words, “everything non-scientific.” Part of this included building the team that would carry out Jamie's lofty research goals. Many of the people he helped recruit at that time are still with the organization twenty-five years later. Two of those early employees were Ken Thompson, now ALS TDI's Vice President of Facility Operations, and Fernando Vieira, our CEO and Chief Scientific Officer. Today, on Endpoints, we're joined by Rob – as well as Ken and Fernando – to talk about what it's been like to see ALS TDI grow from its humble beginnings to one of the world's leading ALS research institutions.Support the show: https://www.als.net/donate/See omnystudio.com/listener for privacy information.
Send us a textDr. Benjamin L. Oakes, Ph.D., is Co-Founder, President, and Chief Executive Officer at Scribe Therapeutics ( https://www.scribetx.com/ ), a molecular engineering company focused on creating best-in-class CRISPR-based therapies that permanently treat the underlying cause of disease. Previously, as an Innovative Genomics Institute Entrepreneurial Fellow, Dr. Oakes focused on the holistic engineering of genome editing technologies to build novel genome editing molecules.Dr. Oakes has contributed to over 35 publications and patent applications across synthetic biology, molecular engineering, CRISPR, and zinc finger-based genetic modification. Dr. Oakes has been named to the MIT Technology Review 35 Innovators Under 35, San Francisco Business Times 40 Under 40, Endpoints 20 Under 40 in Biopharma, Business Insider 30 Under 40 Transforming Healthcare, and the Biocom Life Sciences Catalyst Awards. He received a Ph.D. in Molecular and Cellular Biology from the University of California, Berkeley, in 2017, where he worked in the Doudna Lab and Savage Lab developing CRISPR-Cas9 molecules with enhanced characteristics. Two such projects resulted in distinct versions of synthetic sensing systems that can modify nucleic acids only when triggered by external stimuli, and have found use in both research and pragmatically applied technologies.Prior to his Ph.D., Dr. Oakes received his B.A. in the fields of Philosophy and Neurobiology and worked as a researcher applying unbiased, combinatorial evolution methods to build tens of thousands of “version one” genome editing tools, providing an open source framework for scientists and medical professionals to modify the genome before the discovery of CRISPR technology.#BenjaminOakes #ScribeTherapeutics #MolecularEngineering #CRISPR #InnovativeGenomicsInstitute #JenniferDoudna #MolecularBiology #UniversityOfCalifornia #Berkeley #SyntheticBiology #ZincFingerNucleases #Optogenetics #EmmanuelleCharpentier #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #STEM #Innovation #Technology #Science #ResearchSupport the show
Wed, 21 Aug 2024 21:30:00 GMT http://relay.fm/connected/515 http://relay.fm/connected/515 "Endpoints" 515 Federico Viticci, Stephen Hackett, and Myke Hurley It's a busy week on the show. The guys cover some iPhone rumors, changes at Apple Podcasts, the announcement of Monument Valley 3, and iOS 18's final days in beta, all before discussing the idea of the "Apple cult" starting to fade. It's a busy week on the show. The guys cover some iPhone rumors, changes at Apple Podcasts, the announcement of Monument Valley 3, and iOS 18's final days in beta, all before discussing the idea of the "Apple cult" starting to fade. clean 6047 It's a busy week on the show. The guys cover some iPhone rumors, changes at Apple Podcasts, the announcement of Monument Valley 3, and iOS 18's final days in beta, all before discussing the idea of the "Apple cult" starting to fade. This episode of Connected is sponsored by: NetSuite: The leading integrated cloud business software suite. Vitally: A new era for customer success productivity. Get a free pair of AirPods Pro when you book a qualified meeting. ExpressVPN: High-Speed, Secure & Anonymous VPN Service. Get an extra three months free. KRCS: Get your new Mac with all your preferred specs, with pricing you won't find anywhere else Links and Show Notes: Get Connected Pro: Preshow, postshow, no ads. Submit Feedback Dr. Drang's Follow Up Unwatched: RSS Video Player on the App Store Winston for Reddit Performa Month: The Transition to PowerPC and a New All-in-One – 512 Pixels ten. | the movie. - YouTube Departures #12: 2024 Q&A: Relay Turns 10 - Relay FM New image reveals iPhone 16 Pro in new 'bronze' color - 9to5Mac Bronze-Like iPhone 16 Pro Color Could Be Called 'Desert Titanium' - MacRumors Ungeniused #218: The Dave Matthews Band Bus Incident - Relay FM Upgrade #525: Best of U3 - Relay FM Who is New Martina, the tiktoker who makes smartphone covers – Cosmopolitan Monument Valley 3 Is Heading To Netflix Games Along with the Series' First Two Installments - MacStories Developers Claim Apple Arcade is 'Directionless' - MacStories Netflix Games | Netflix Help Center Netflix has a great video game catalog, actually | Polygon Netflix Considers Ways to Make Money From Videogames in Possible Pivot - WSJ Can Netflix Profit from Video Games? | Nasdaq Stephen's HomeKit Page Is this the slow decline of the Apple “cult”? - Birchtree The Slow Decline of the Apple
Wed, 21 Aug 2024 21:30:00 GMT http://relay.fm/connected/515 http://relay.fm/connected/515 Federico Viticci, Stephen Hackett, and Myke Hurley It's a busy week on the show. The guys cover some iPhone rumors, changes at Apple Podcasts, the announcement of Monument Valley 3, and iOS 18's final days in beta, all before discussing the idea of the "Apple cult" starting to fade. It's a busy week on the show. The guys cover some iPhone rumors, changes at Apple Podcasts, the announcement of Monument Valley 3, and iOS 18's final days in beta, all before discussing the idea of the "Apple cult" starting to fade. clean 6047 It's a busy week on the show. The guys cover some iPhone rumors, changes at Apple Podcasts, the announcement of Monument Valley 3, and iOS 18's final days in beta, all before discussing the idea of the "Apple cult" starting to fade. This episode of Connected is sponsored by: NetSuite: The leading integrated cloud business software suite. Vitally: A new era for customer success productivity. Get a free pair of AirPods Pro when you book a qualified meeting. ExpressVPN: High-Speed, Secure & Anonymous VPN Service. Get an extra three months free. KRCS: Get your new Mac with all your preferred specs, with pricing you won't find anywhere else Links and Show Notes: Get Connected Pro: Preshow, postshow, no ads. Submit Feedback Dr. Drang's Follow Up Unwatched: RSS Video Player on the App Store Winston for Reddit Performa Month: The Transition to PowerPC and a New All-in-One – 512 Pixels ten. | the movie. - YouTube Departures #12: 2024 Q&A: Relay Turns 10 - Relay FM New image reveals iPhone 16 Pro in new 'bronze' color - 9to5Mac Bronze-Like iPhone 16 Pro Color Could Be Called 'Desert Titanium' - MacRumors Ungeniused #218: The Dave Matthews Band Bus Incident - Relay FM Upgrade #525: Best of U3 - Relay FM Who is New Martina, the tiktoker who makes smartphone covers – Cosmopolitan Monument Valley 3 Is Heading To Netflix Games Along with the Series' First Two Installments - MacStories Developers Claim Apple Arcade is 'Directionless' - MacStories Netflix Games | Netflix Help Center Netflix has a great video game catalog, actually | Polygon Netflix Considers Ways to Make Money From Videogames in Possible Pivot - WSJ Can Netflix Profit from Video Games? | Nasdaq Stephen's HomeKit Page Is this the slow decline of the Apple “cult”? - Birchtree The Slow Decline of
Ergo, one of Ireland's leading IT services providers, has achieved the Microsoft Modernise Endpoints specialisation, a recognition given to Microsoft partners globally who demonstrate deep knowledge, extensive experience, and proven success in delivering holistic solutions designed for the hybrid workplace. As the world of work changes and businesses continue to operate hybrid models of working, organisations need to manage and enable secure access to corporate resources across mobile, desktop, and virtual endpoints to better enable their workforce and set them up for success. This includes devices users need, operating systems that are secure by design, endpoint management solutions, and collaborative applications that are accessible from anywhere. Microsoft Capabilities The Ergo team works to embed a culture of collaboration and secure hybrid working inside global multi-site organisations, using Microsoft solutions such as Microsoft Intune, Microsoft 365, Windows Autopilot, Microsoft Defender for Endpoint, Microsoft Entra and Microsoft Azure Virtual Desktop Infrastructure to bring disparate workforces together for a seamless experience. Speaking on the recognition, Gerry Hampson, Client Management Practice Lead at Ergo, and Microsoft MVP, said: "In a world where workplaces are increasingly disparate, it is essential that organisations are set up for success when managing teams across multiple locations and geographies." "This achievement is testament to the hard work and dedication of the team here in Ergo, who are steadfast in their commitment to ensuring that our customers are set up for success through preparing them for today, while planning for tomorrow." Paul Chawke, Partner Development Manager at Microsoft said: "Ergo has a longstanding, 30-year long history with Microsoft achieving technological advancements and innovation in Ireland. This achievement recognises the work that Ergo are carrying out when it comes to equipping organisations for success through Modernize Endpoint solutions." Ergo has extensive knowledge and capabilities in the area of modern work, with one of the largest Microsoft practices in Ireland and five Microsoft MVPs (Most Valuable Professionals, the highest accolade a Microsoft engineer can be awarded), three of whom contribute to modern work areas such as Microsoft 365 Development and Enterprise Mobility. Ergo is also a Microsoft Solution Partner for Modern Work with specialisations in adoption and change management, meetings and meeting rooms for Microsoft Teams, and Modernise Endpoints. This expertise was recognised as Ergo took home the Microsoft Partner of the Year Award 2024. This is the sixth time Ergo has won the Country of the Year Award making it the most recognised Microsoft Partner in Ireland. See more stories here.
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by bone marrow fibrosis, extramedullary hematopoiesis, and splenomegaly, often resulting in... The post Unmet treatment needs in MF: managing prefibrotic disease & thrombocytopenia, novel agents & endpoints for clinical trials appeared first on VJHemOnc.
July 26, 2024: Michael Robinson, VP of Healthcare Solutions for the Americas at Omnissa, joins Bill for the news. They delve into the current state of cybersecurity in healthcare, emphasizing the rise in ransomware demands and the crucial need for mature security postures in health systems. How can health systems better manage the increasing threat vectors from device proliferation? What role does AI play in enhancing security measures, and how effective is the adoption of zero-trust architecture in preventing breaches? The conversation also touches on the evolving use of Gen AI in healthcare, particularly in administrative versus clinical applications. As Gen AI tools become more prevalent, what are the implications for patient interactions and the necessity of human oversight in AI-driven healthcare solutions?Key Points:00:28 Michael Robinson from Omnissa00:58 Omnissa: Company Background and Offerings02:56 Ransomware and Security in Healthcare06:52 Password Management and Zero Trust11:03 Gen AI: Opportunities and ChallengesNews articles:Ransomware Extortion Demands Soar to $5.2M per AttackAI Ushers in New Era of Global Healthcare Equity and Efficiency
IGEL helps companies to quickly recover, whenever productive work comes to a halt due to an IT outage.IGEL offers a secure read-only lightweight Linux Operating System allowing you to convert existing PC's to IGEL OS or boot from USB (thus not affecting the existing Operating System or data) whilst in a Disaster Recovery situation, allowing users to connect to services such as VDI, DaaS andor WEB and SaaS applications.In a DR scenario IGEL OS will work without the need for management infrastructure to be setup and configured, simply boot to IGEL OS, download evaluation licenses for 90 days; install any client applications you require to connect to your VDI, DaaS andor WEB and SaaS applications and get your users back up and running FAST.This may also have the advantage of granting the IT team breathing space whilst they continue to troubleshoot any ongoing outages.Host: Andy WhitesideCo-host: Chris Feeney
Welcome to the Heroes of IT podcast, hosted by Automox's Ashley Smith. In this podcast, Ashley interviews IT heroes ready to share their insights, successes, challenges, and stories from the field. Join us as we talk endpoint management tips and tricks, how to overcome hurdles, and celebrate IT heroes' contributions to modern technology.
All links and images for this episode can be found on CISO Series. This week's episode is hosted by me, David Spark (@dspark), producer of CISO Series and Andy Ellis (@csoandy), operating partner, YL Ventures. Joining us is our guest and winner of Season 2 of Capture the CISO, Russell Spitler, CEO and co-founder, Nudge Security. In this episode: The Gordian knot of EDR Can we keep up with patching? Making AI practical Standardization or granularity? Thanks to our podcast sponsor, ThreatLocker! ThreatLocker® is a global leader in Zero Trust endpoint security offering cybersecurity controls to protect businesses from zero-day attacks and ransomware. ThreatLocker operates with a default deny approach to reduce the attack surface and mitigate potential cyber vulnerabilities. To learn more and start your free trial, visit ThreatLocker.com.
In this episode, Etienne Nichols is joined by Shaherah Yancy, CEO of Research Lifecycle Solutions. They dive deep into the critical importance of developing robust clinical and regulatory strategies for MedTech companies. Shaherah shares her extensive experience in the field, providing practical advice on securing funding, ensuring market access, and achieving market adoption. They explore the nuances of clinical evidence, the significance of strategic planning, and the role of advisory panels in navigating the MedTech landscape.Key Timestamps:00:00 - 03:00 Introduction and Sponsor Message03:01 - 05:20 Introduction to Shaherah Yancy and her background05:21 - 10:30 Importance of Clinical and Regulatory Strategies10:31 - 17:15 Challenges of Securing Funding and Developing Strategy17:16 - 25:45 Differences Between Market Access and Market Adoption25:46 - 33:50 Developing Effective Clinical Plans for Market Adoption33:51 - 39:40 Importance of Evidence and Study Design39:41 - 48:00 Examples and Case Studies from Early Stage Companies48:01 - 55:15 Endpoints for Market Adoption55:16 - 01:02:30 Strategies for Novel Technologies01:02:31 - 01:07:45 Final Advice and Contact InformationNotable Quotes:"Market access is a milestone. Market adoption is the goal." - Shaherah Yancy"Understanding the problem you're solving is crucial for your strategy." - Shaherah Yancy"Don't be afraid of clinical evidence; it's your key to success." - Shaherah YancyKey Takeaways:MedTech Trends:Strategic Planning is Essential: Early and comprehensive planning for clinical and regulatory strategies can significantly enhance a company's chances of success.Clinical Evidence is Critical: Collecting robust clinical data is vital for both market access and long-term market adoption.Market Adoption Over Market Access: The ultimate goal should be market adoption, not just getting to market.Practical Tips:Form Advisory Panels: Engage with surgeons and clinical experts early to guide product development and market entry strategies.Comprehensive Studies: Design studies that include both primary endpoints for regulatory approval and secondary endpoints for market adoption.Prepare for Limited Market Releases: Use limited market releases to gather real-world evidence and refine products before a full launch.References:Research Lifecycle Solutions: Shaherah Yancy's company, specializing in clinical and regulatory strategies for MedTech. RLC SolutionsGreenlight Guru Clinical: The sponsor of this episode, offering a platform for streamlining clinical trials. Greenlight Guru ClinicalEtienne Nichols LinkedIn: Connect with Etienne on LinkedIn for more insights. Etienne Nichols LinkedInMedTech 101:Clinical Evidence: Data collected from clinical trials and studies to demonstrate the safety and efficacy of a medical device.510(k) Clearance: A premarket submission made to the FDA to demonstrate that the device to be marketed is at least as safe and effective as a legally...
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Gilead twice-yearly HIV shot delivers zero infections in trial The bad — Takeda epilepsy drug misses endpoints in trials The ugly — Eli Lilly goes after counterfeiters
Eugenia and Jeff talk with Andy Poulter (PM for Edge DX) about what's now with Edge DX. For instance, did you know Edge DX now has device averages? Listen in and learn what's new.
Welcome back for another new episode, Data Center Therapy aficionados! This week, our adventurous and hard-working hosts, Matt “Master Link” Yette and Matt “Chromed Crankset” Cozzolino open up the virtual studios to IVOXY's own Ryan “Security Gusset” Grelck, who joins the fellas to talk all things endpoint-related for the first part of the podcast.In addition to discussions of all things client-related, the crew also discuss:The differences between endpoint protection (EPP) and endpoint detection and response (EDR).SentinelOne's purple.ai feature and automated root cause analysis (RCA).Microsoft's Recall feature for Copilot+ PCs, and its security implications.The browser wars, Firefox, and how Chromium code maintenance impacts modern browser platforms.With all those topics and more, including the upcoming Q3 and Q4 classes from IVOXY, the Matts and Ryan also briefly cover the newer software suites now included in VMware vSphere Foundation and VMware Cloud Foundation. We hope you have as much fun listening to the show as much as we had making it, and if you do, be sure to tell three friends, like and subscribe wherever you find your quality podcasts. Thanks for joining us once again and we'll see you in an IVOXY class, on a free webinar or on the next episode of DCT. Ciao for now!
Recorded at the first annual “HemOnc Pulse” Live meeting, this episode features a panel discussion on unanswered questions in myeloproliferative neoplasms (MPN) with Naveen Pemmaraju, MD, of the University of Texas MD Anderson Cancer Center; Ruben Mesa, MD, of the Atrium Health cancer service line; Sanam Loghavi, MD, of the MD Anderson Cancer Center; and Olatoyosi Odenike, MD, of the University of Chicago Medicine.
Jennifer Goldsack of DiME talks in this podcast about the ROI for digital endpoints for pharma. Data shows digital endpoints drives meaningful engagement with healthcare providers.
The latest episode of Preparing for a Cell and Gene Future features a discussion between Jamie Pierson (Program Lead within Parexel's Cell and Gene Center of Excellence) and Kim MacDonnell (Associate Director for Rare Diseases). They consider uses of surrogate markers as endpoints in rare disease development and look ahead to positive directions established by FDA's current initiatives.
Kids Quest to Cure ALS is an organization for kids, by kids. Their mission is to get young people involved in the fight against ALS. The group was founded by kids in the US and Canada – all of whom have been affected by a loved one's ALS diagnosis. They are encouraging people under the age of 18 across both countries to band together to help raise funds for ALS research and bring awareness to the disease. Today, on Endpoints, we're joined by several members of the Kids Quest steering committee to tell us more about the inspiration behind their mission, and why it's important to involve young people in the fight against ALS.Support the show: https://www.als.net/donate/See omnystudio.com/listener for privacy information.
In this conversation, the panel discusses challenges in MASH Drug Development that are centered around efficacy endpoints and NAS scoring.This conversation starts with Will Alazawi suggesting that the MASH clinical trial field suffers from the previous experience with Hepatitis C, where medications became capable of eradicating disease in a fairly linear fashion. He suggests that MASH trials undervalue the value of simply preventing progression, which leads Sven Francque to note that preventing progression to cirrhosis is now accepted by regulators as an endpoint. Roger Green refers to last week's episode (S5 – E11), in which Michael Charlton said he would continue Rezdiffra therapy for any patient exhibiting a lack of progression, and that a clinically valuable efficacy measure must be applicable to true clinical practice. Roger goes on to recall Sven's earlier comment that having the NAS score as a co-endpoint complicates the challenge of proving efficacy because the scale is relatively blunt and not well suited to the task at hand. He suggests that an activity score focused on inflammation and ballooning might function better than one including steatosis. Jörn Schattenberg suggests that this depends on the drug's Mode of Action. Sven reminds the group that Stephen Harrison presented a paper at AASLD suggesting the approach Sven describes: splitting NAS into separate steatosis and activity scores, with the activity score based on lobular inflammation and ballooning. Roger asks whether the widely reported challenges in coding ballooning will render this method less valuable. Sven says it might, and states the challenge stems from the lack of detail in the scoring system. Louise Campbell suggests that in addition to stabilizing MASH, endpoints might look at related metabolic diseases that poor liver health can affect. Will agrees, noting that many patients may be on other metabolic agents at the outset of a trial or, more challenging, the definition of "good practice" might change during the trial, which can add variability to the sample. He wonders whether differences in placebo rates can provide insight on this issue. Roger recalls a comment from Dean Tai of HistoIndex (S4 - E50.4) that some HistoIndex AI-driven analyses produce consistent placebo rates of ~33%, with efficacy rates far higher.
Today on Cyber Work, our deep-dive into manufacturing and operational technology (OT) cybersecurity brings us to the problem of endpoint security. Tom Molden, CIO of Global Executive Engagement at Tanium, has been grappling with these problems for a while. We talk about his early, formative tech experiences (pre-Windows operation system!), his transformational position moving from fiscal strategy and implementation into his first time as chief information officer and talk through the interlocking problems that come from connected manufacturing devices and the specific benefits and challenges to be found in strategizing around the endpoints. All of the endpoints.0:00 - Manufacturing and endpoint security1:44 - Tom Molden's early interest in computers4:06 - Early data usage6:26 - Becoming a CIO10:29 - Difference between a CIO and CISO14:57 - Problems for manufacturing companies 18:45 - Best CIO problems to solve in manufacturing22:51 - Security challenges of manufacturing 26:00 - The scop of endpoint issues 33:27 - Endpoints in manufacturing security37:12 - How to work in manufacturing security39:29 - Manufacturing security skills gaps41:54 - Gain manufacturing security work experience43:41 - Tom Molden's best career advice received46:26 - What is Tanium 47:58 - Learn more about Tom Molden48:34 - Outro – Get your FREE cybersecurity training resources: https://www.infosecinstitute.com/free– View Cyber Work Podcast transcripts and additional episodes: https://www.infosecinstitute.com/podcastAbout InfosecInfosec's mission is to put people at the center of cybersecurity. We help IT and security professionals advance their careers with skills development and certifications while empowering all employees with security awareness and phishing training to stay cyber-safe at work and home. More than 70% of the Fortune 500 have relied on Infosec Skills to develop their security talent, and more than 5 million learners worldwide are more cyber-resilient from Infosec IQ's security awareness training. Learn more at infosecinstitute.com.
Dr Bernardo Goulart (US Food and Drug Administration) discusses his paper on correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00040-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
Do you know how to interpret the results of recent phase 3 clinical trials in patients with transthyretin amyloid cardiomyopathy (ATTR-CM)? Credit available for this activity expires: 3/22/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000444?ecd=bdc_podcast_libsyn_mscpedu
Scott Berdahl, CEO of Snowline Gold ("Snowline" or the "Company") (TSX.V:SGD - OTCQB:SNWGF) joins me to recap the recent drill results from the Valley Zone on the Rogue Project, in the Yukon. The last of the results from the Valley Zone from the 2023 drill program were released in a few news releases this year. There has also been news on a new gold target, the Aurelius target, and a new management team member, Brian Hegarty as VP of Sustainability and External Relations. To better understand all the drilling at Valley, refer to Figure 2 from the January 22nd news release. I ask Scott about Hole 70 which was drilled in a different direction from all the other holes to date. We also discuss where gold mineralization is open and where the Company is planning on drilling this year. This ties into the new target, Aurelius, that the Company will be following up on. If you have any follow up questions for Scott please email me at Fleck@kereport.com. Click here to visit the Snowline website and read over all the recent news. Figure 2 – Plan view of the Rogue Project's Valley target showing analytical results from previous and current drilling, along with drill traces of outstanding holes. Note that to display new results, current holes are plotted above previous holes regardless of relative depths. The system remains open in multiple directions, including to depth. Endpoints for sections A (Figure 1) and B (Figure 3) are indicated on the map.
In 2023, Insilico Medicine—a biotech company developing medications with a heavy reliance on AI—used AI to develop an experimental drug for the incurable lung disease idiopathic pulmonary fibrosis. The treatment is in mid-stage trials in the US and China, with some results expected in early 2025. Biotech is one of the fields that has been using generative AI for years, even before ChatGPT brought the technology to public view. Latest technology is essential in drug development. However, the convergence of digital health and pharma seems less clear. Digital health apps started gaining popularity around 2015, and at that time, it seemed all pharma companies were trying to figure out what they could gain from apps, so they financed accelerators and incubators one after the other. We've seen many ideas about how Pharma should or could use digital health. In the last few years, there have been many notorious cases when partnerships failed—a seemingly unicorn, Proteus, which designed digital sensors-equipped pills, went bankrupt in 2019 after Otsuka Pharmaceuticals pulled out of a funding round. Pear Therapeutics, the guiding star in the DTx space and the leader in FDA-cleared prescription digital therapeutics, partnered with Novartis, but in the end, the company filed for bankruptcy in 2023. So where is Pharma in relation to digital health and digital therapeutics? In this episode, Amir Lahav shares his thoughts about the impact of AI on biotech, the state of decentralized clinical trials, and the potential of technology for improved drug development, clinical trials, and patient responses. Newsletter: https://fodh.substack.com/ www.facesofdigitalhealth.com Show notes: [00:02:00] The Convergence of Digital Health and Pharma Discussion on the role of digital health apps in pharmaceuticals. The rise and fall of pharma and tech company partnerships, with examples like Proteus and Peer Therapeutics. [00:06:00] AI Trends in Biotech and Pharma [00:08:00] Enhancing Clinical Trials with AI and continuous patient monitoring [00:10:00] The Importance of Data in Clinical Trials [00:12:00] The Reality of Oncology Trials and Endpoints [00:14:00] Quality of Life in Medicine as the Endpoint [00:16:00] The Rise of Decentralized Clinical Trials [00:18:00] Pharma's Evolving Digital Health Strategies [00:22:00] Impact on Digital Health Industry [00:24:00] Collaboration and Sharing Knowledge in the Pharma Industry [00:26:00] The need for long-term investment and strategic piloting of digital health solutions [00:28:00] What Inspires in Pharma and Biotech in Personalized Treatments [00:30:00] The State of Precision Medicine and Targeted Therapies [00:34:00] The Role of Pharmacogenomics [00:36:00] Anticipations for 2024 and Beyond
IGEL's Preventative Security Model™ provides a secure endpoint OS for your use case.It's clear from the headlines that today's approach to endpoint security isn't working: take your OS, install antivirus, the latest XDR and DLP, make a lot of settings, harden that with custom scripts, install your applications, keep updating those applications and the OS and the AV and DLP….. and hope that all these steps keep the wolf from the door and the ransomware out of your systems. Does your business financial data, personal health information or any other data feel secure?With many of today's workloads moving from the endpoint to SaaS, DaaS, VDI or being accessed through secure browsers, and many organizations looking at how to apply Zero Trust, isn't it time to re-evaluate the endpoint?What if you could put an endpoint OS into your workforce's hands that was designed for the cloud-first world that doesn't need high levels of care and feeding to remain healthy? Something that is more robust by its nature, that had built-in preventative components or measures, as in “Prevention is better than cure.”?IGEL OS applies a number of core principles that make it a secure choice as an endpoint OS – the Preventative Security Model™.Host: Andy WhitesideCo-host: Chris Feeney
One of the most common misconceptions about ALS is that it only affects older white men. In reality, the disease can affect anyone of any age – and of any ethnicity. Many Shades of ALS, a team within the I AM ALS organization, is working hard to dispel some of these misconceptions. Their mission is to bring attention to people of color living with ALS and the unique challenges they often face – as well as providing resources for their mental, physical, and social well-being. Juan Reyes is a veteran living with ALS, an advocate, and co-chair of Many Shades of ALS team. Lakeia Nard is a member of the team who lost her son, King'nazir, to a rare form of pediatric ALS and also runs her own nonprofit, Melanin Children Matter. Today, on Endpoints, they join us to talk about how the team came together, its mission, and how the ALS research and medical communities could be better serving people of color with the disease.Support the show: https://www.als.net/donate/See omnystudio.com/listener for privacy information.
Today, I'm thrilled to be in conversation with none other than Nico Gastaldi, one of the best thrust vector aerobatic jet pilots worldwide. Coming to us from France, Nico brings his wealth of experience with hundreds of thrust vector flights on J-10, Mephisto, and Ares, offering us a masterclass in the intricate world of thrust vectoring aerobatics.Join us as Nico walks us through his process for gear selection, assembly, radio setup, trimming, center of gravity adjustment, and gyro tuning – all essential elements for achieving max performance in turbine jets.But that's not all; Nico opens up about his latest ventures with PAU and RCGadgetz. We not only delve into their just-announced Pulse sport jet but also get some initial details into a future thrust vector jet currently in development by Nico and the PAU team, anticipated for release later this year.Follow Nico in Facebook: https://www.facebook.com/nico.gastaldi.7RcGadgetz: https://rcgadgetz.com/PAU USA: https://flypauusa.com/Contents:00:00: Intro and getting started in RC07:26: Transitioning to 3D flying with jets09:45: How to properly setup a thrust vector jet for aerobatics and 3D. 10:50: Assembly and component selection15:45: Center of gravity20:13: Trimming process24:00: Endpoints, exponential, rates30:17: Gyro tuning50:55: Thrust vector always on?54:24: Max deflections on surfaces and thrust vector59:35: Freestyle with jets1:06:28: Working with RCGadgetz, PAU Pulse jet and new delta wing thrust vector jet1:12:45: Flying and coaching in India and where people struggle with jets
In the aftermath of the 2020 biotech surge and its subsequent contraction in 2022, the biotech industry has been characterized by significant volatility. There were 21 biotechnology IPOs in 2022, a notable decrease from the record-breaking 104 IPOs in 2021.To review the highs and lows of 2023 and explore what lies ahead in 2024, distinguished biotech analyst and co-founder of Endpoints News John Carroll joins Hercules Capital's Janice Bourque. Carroll brings 45 years of award-winning journalism, and a specialization in biopharma spanning over two decades to discuss the biggest pharma deals and surprises of 2023, the impact of AI on drug development, the future of biotech in Asia, and much more. Topics Include:The biggest pharma deals and surprises of 2023AI's impact on drug developmentWhether or not the Inflation Reduction Act will impact pricingJohn's major lessons from 2023The future of biotech in AsiaThe greatest concerns for the biotech industry going into 2024John's hopes for the industry in the new yearAnd other topics…------------------John D. Carroll is a biotech analyst and writer with decades of prize-winning experience in journalism. A co-founder of Endpoints News, he has covered biopharma for the past 15 years. Carroll has been quoted by The New York Times, The New Yorker, Financial Times, The Times of London and more. He's also keynoted at biotech gatherings around the world and addressed student audiences at MIT and Harvard. Carroll has contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press. He spent 6 years as editor and publisher of the Dallas Business Journal, was publisher of Texas Business and early in his career was part of a Pulitzer Prize-winning team of reporters and editors at the Kansas City Star & Times.Resources Mentioned:Endpoints News: https://endpts.com/ Connect with John:LinkedIn: https://www.linkedin.com/in/john-carroll-884aa410/
This is a recap of the top 10 posts on Hacker News on December 11th, 2023.This podcast was generated by wondercraft.ai(00:39): Beeper Mini is backOriginal post: https://news.ycombinator.com/item?id=38602575&utm_source=wondercraft_ai(02:28): Mixtral of expertsOriginal post: https://news.ycombinator.com/item?id=38598559&utm_source=wondercraft_ai(04:23): Mistral: Our first AI endpoints are available in early accessOriginal post: https://news.ycombinator.com/item?id=38598568&utm_source=wondercraft_ai(06:12): We don't have official RSS feed support for now, but we're working on a solutionOriginal post: https://news.ycombinator.com/item?id=38598983&utm_source=wondercraft_ai(07:54): FISA "reform" bill would greatly expand the entities forced to surveil usersOriginal post: https://news.ycombinator.com/item?id=38605525&utm_source=wondercraft_ai(09:46): Tohands – Smart calculator for small businessesOriginal post: https://news.ycombinator.com/item?id=38599270&utm_source=wondercraft_ai(11:25): Jury decides Google has illegal monopoly in app store fightOriginal post: https://news.ycombinator.com/item?id=38607474&utm_source=wondercraft_ai(12:49): GigaGPT: GPT-3 sized models in 565 lines of codeOriginal post: https://news.ycombinator.com/item?id=38603207&utm_source=wondercraft_ai(14:57): Earliest Carpenters: 476k-year-old log structure discovered in ZambiaOriginal post: https://news.ycombinator.com/item?id=38598742&utm_source=wondercraft_ai(16:51): Bad science and bad statistics in the courtroom convict innocent peopleOriginal post: https://news.ycombinator.com/item?id=38601960&utm_source=wondercraft_aiThis is a third-party project, independent from HN and YC. Text and audio generated using AI, by wondercraft.ai. Create your own studio quality podcast with text as the only input in seconds at app.wondercraft.ai. Issues or feedback? We'd love to hear from you: team@wondercraft.ai
When dealing with a disease like ALS, it can be hard to know where to turn for reliable information and advice. While your doctor and care team might be able to provide some answers to your questions, there are many topics that they might not be equipped to handle. There are many resources available on the internet, but it can be hard to know if you've found a reputable source. Roon is an app that help solve this problem. It provides answers to questions about disease, including ALS, in the form of short video clips featuring researchers, doctors, caregivers, people with the disease, and more. They provide information about topics like treatments, current research into the causes of the disease, and advice about to day-to-day life. Today, on Endpoints, we're joined by Roon's co-founder and CEO Vikram Bhaskaran to tell us more about the app, and how his own personal experience with ALS helped inspire it.Support the show: https://www.als.net/donate/See omnystudio.com/listener for privacy information.
Seif Lotfy, Co-Founder and CTO at Axiom, joins Corey on Screaming in the Cloud to discuss how and why Axiom has taken a low-cost approach to event data. Seif describes the events that led to him helping co-found a company, and explains why the team wrote all their code from scratch. Corey and Seif discuss their views on AWS pricing, and Seif shares his views on why AWS doesn't have to compete on price. Seif also reveals some of the exciting new products and features that Axiom is currently working on. About SeifSeif is the bubbly Co-founder and CTO of Axiom where he has helped build the next generation of logging, tracing, and metrics. His background is at Xamarin, and Deutche Telekom and he is the kind of deep technical nerd that geeks out on white papers about emerging technology and then goes to see what he can build.Links Referenced: Axiom: https://axiom.co/ Twitter: https://twitter.com/seiflotfy TranscriptAnnouncer: Hello, and welcome to Screaming in the Cloud with your host, Chief Cloud Economist at The Duckbill Group, Corey Quinn. This weekly show features conversations with people doing interesting work in the world of cloud, thoughtful commentary on the state of the technical world, and ridiculous titles for which Corey refuses to apologize. This is Screaming in the Cloud.Corey: Welcome to Screaming in the Cloud. I'm Corey Quinn. This promoted guest episode is brought to us by my friends, and soon to be yours, over at Axiom. Today I'm talking with Seif Lotfy, who's the co-founder and CTO of Axiom. Seif, how are you?Seif: Hey, Corey, I am very good, thank you. It's pretty late here, but it's worth it. I'm excited to be on this interview. How are you today?Corey: I'm not dead yet. It's weird, I see you at a bunch of different conferences, and I keep forgetting that you do in fact live half a world away. Is the entire company based in Europe? And where are you folks? Where do you start and where do you stop geographically? Let's start there. We over—everyone dives right into product. No, no, no. I want to know where in the world people sit because apparently, that's the most important thing about a company in 2023.Seif: Unless you ask Zoom because they're undoing whatever they did. We're from New Zealand, all the way to San Francisco, and everything in between. So, we have people in Egypt and Nigeria, all around Europe, all around the US… and UK, if you don't consider it Europe anymore.Corey: Yeah, it really depends. There's a lot of unfortunate naming that needs to get changed in the wake of that.Seif: [laugh].Corey: But enough about geopolitics. Let's talk about industry politics. I've been a fan of Axiom for a while and I was somewhat surprised to realize how long it had been around because I only heard about you folks a couple of years back. What is it you folks do? Because I know how I think about what you're up to, but you've also gone through some messaging iteration, and it is a near certainty that I am behind the times.Seif: Well, at this point, we just define ourselves as the best home for event data. So, Axiom is the best home for event data. We try to deal with everything that is event-based, so time-series. So, we can talk metrics, logs, traces, et cetera. And right now predominantly serving engineering and security.And we're trying to be—or we are—the first cloud-native time-series platform to provide streaming search, reporting, and monitoring capabilities. And we're built from the ground up, by the way. Like, we didn't actually—we're not using Parquet [unintelligible 00:02:36] thing. We're completely everything from the ground up.Corey: When I first started talking to you folks a few years back, there were two points to me that really stood out, and I know at least one of them still holds true. The first is that at the time, you were primarily talking about log data. Just send all your logs over to Axiom. The end. And that was a simple message that was simple enough that I could understand it, frankly.Because back when I was slinging servers around and you know breaking half of them, logs were effectively how we kept track of what was going on, where. These days, it feels like everything has been repainted with a very broad brush called observability, and the takeaway from most company pitches has been, you must be smarter than you are to understand what it is that we're up to. And in some cases, you scratch below the surface and realize it no, they have no idea what they're talking about either and they're really hoping you don't call them on that.Seif: It's packaging.Corey: Yeah. It is packaging and that's important.Seif: It's literally packaging. If you look at it, traces and logs, these are events. There's a timestamp and just data with it. It's a timestamp and data with it, right? Even metrics is all the way to that point.And a good example, now everybody's jumping on [OTel 00:03:46]. For me, OTel is nothing else, but a different structure for time series, for different types of time series, and that can be used differently, right? Or at least not used differently but you can leverage it differently.Corey: And the other thing that you did that was interesting and is a lot, I think, more sustainable as far as [moats 00:04:04] go, rather than things that can be changed on a billboard or whatnot, is your economic position. And your pricing has changed around somewhat, but I ran a number of analyses on your cost that you were passing on to customers and my takeaway was that it was a little bit more expensive to store data for logs in Axiom than it was to store it in S3, but not by much. And it just blew away the price point of everything else focused around logs, including AWS; you're paying 50 cents a gigabyte to ingest CloudWatch logs data over there. Other companies are charging multiples of that and Cisco recently bought Splunk for $28 billion because it was cheaper than paying their annual Splunk bill. How did you get to that price point? Is it just a matter of everyone else being greedy or have you done something different?Seif: We looked at it from the perspective of… so there's the three L's of logging. I forgot the name of the person at Netflix who talked about that, but basically, it's low costs, low latency, large scale, right? And you will never be able to fulfill all three of them. And we decided to work on low costs and large scale. And in terms of low latency, we won't be low as others like ClickHouse, but we are low enough. Like, we're fast enough.The idea is to be fast enough because in most cases, I don't want to compete on milliseconds. I think if the user can see his data in two seconds, he's happy. Or three seconds, he's happy. I'm not going to be, like, one to two seconds and make the cost exponentially higher because I'm one second faster than the other. And that's, I think, that the way we approached this from day one.And from day one, we also started utilizing the idea of existence of Open—Object Storage, we have our own compressions, our own encodings, et cetera, from day one, too, so and we still stick to that. That's why we never converted to other existing things like Parquet. Also because we are a Schema-On-Read, which Parquet doesn't allow you really to do. But other than that, it's… from day one, we wanted to save costs by also making coordination free. So, ingest has to be coordination free, right, because then we don't run a shitty Kafka, like, honestly a lot—a lot of the [logs 00:06:19] companies who running a Kafka in front of it, the Kafka tax reflects in what they—the bill that you're paying for them.Corey: What I found fun about your pricing model is it gets to a point that for any reasonable workload, how much to log or what to log or sample or keep everything is no longer an investment decision; it's just go ahead and handle it. And that was originally what you wound up building out. Increasingly, it seems like you're not just the place to send all the logs to, which to be honest, I was excited enough about that. That was replacing one of the projects I did a couple of times myself, which is building highly available, fault-tolerant, rsyslog clusters in data centers. Okay, great, you've gotten that unlocked, the economics are great, I don't have to worry about that anymore.And then you started adding interesting things on top of it, analyzing things, replaying events that happen to other players, et cetera, et cetera, it almost feels like you're not just a storage depot, but you also can forward certain things on under a variety of different rules or guises and format them as whatever on the other side is expecting them to be. So, there's a story about integrating with other observability vendors, for example, and only sending the stuff that's germane and relevant to them since everyone loves to charge by ingest.Seif: Yeah. So, we did this one thing called endpoints, the number one. Endpoints was a beginning where we said, “Let's let people send us data using whatever API they like using, let's say Elasticsearch, Datadog, Honeycomb, Loki, whatever, and we will just take that data and multiplex it back to them.” So, that's how part of it started. This allows us to see, like, how—allows customers to see how we compared to others, but then we took it a bit further and now, it's still in closed invite-only, but we have Pipelines—codenamed Pipelines—which allows you to send data to us and we will keep it as a source of truth, then we will, given specific rules, we can then ship it anywhere to a different destination, right, and this allows you just to, on the fly, send specific filter things out to, I don't know, a different vendor or even to S3 or you could send it to Splunk. But at the same time, you can—because we have all your data, you can go back in the past, if the incident happens and replay that completely into a different product.Corey: I would say that there's a definite approach to observability, from the perspective of every company tends to visualize stuff a little bit differently. And one of the promises of OTel that I'm seeing that as it grows is the idea of oh, I can send different parts of what I'm seeing off to different providers. But the instrumentation story for OTel is still very much emerging. Logs are kind of eternal and the only real change we've seen to logs over the past decade or so has been instead of just being plain text and their positional parameters would define what was what—if it's in this column, it's an IP address and if it's in this column, it's a return code, and that just wound up being ridiculous—now you see them having schemas; they are structured in a variety of different ways. Which, okay, it's a little harder to wind up just cat'ing a file together and piping it to grep, but there are trade-offs that make it worth it, in my experience.This is one of those transitional products that not only is great once you get to where you're going, from my playing with it, but also it meets you where you already are to get started because everything you've got is emitting logs somewhere, whether you know it or not.Seif: Yes. And that's why we picked up on OTel, right? Like, one of the first things, we now support… we have an OTel endpoint natively bec—or as a first-class citizen because we wanted to build this experience around OTel in general. Whether we like it or not, and there's more reasons to like it, OTel is a standard that's going to stay and it's going to move us forward. I think of OTel as will have the same effect if not bigger as [unintelligible 00:10:11] back of the day, but now it just went away from metrics, just went to metrics, logs, and traces.Traces is, for me, very interesting because I think OTel is the first one to push it in a standard way. There were several attempts to make standardized [logs 00:10:25], but I think traces was something that OTel really pushed into a proper standard that we can follow. It annoys me that everybody uses a different bits and pieces of it and adds something to it, but I think it's also because it's not that mature yet, so people are trying to figure out how to deliver the best experience and package it in a way that it's actually interesting for a user.Corey: What I have found is that there's a lot that's in this space that is just simply noise. Whenever I spend a protracted time period working on basically anything and I'm still confused by the way people talk about that thing, months or years later, I'm starting to get the realization that maybe I'm not the problem here. And I'm not—I don't mean this to be insulting, but one of the things I've loved about you folks is I've always understood what you're saying. Now, you can hear that as, “Oh, you mean we talk like simpletons?” No, it means what you're talking about resonates with at least a subset of the people who have the problem you solve. That's not nothing.Seif: Yes. We've tried really hard because one of the things we've tried to do is actually bring observability to people who are not always busy or it's not part of their day to day. So, we try to bring into [Versal 00:11:37] developers, right, with doing a Versal integration. And all of a sudden, now they have their logs, and they have a metrics, and they have some traces. So, all of a sudden, they're doing the observability work. Or they have actual observability, for their Versal based, [unintelligible 00:11:54]-based product.And we try to meet the people where they are, so we try to—instead of actually telling people, “You should send us data.”—I mean, that's what they do now—we try to find, okay, what product are you using and how can we grab data from there and send it to us to make your life easier? You see that we did that with Versal, we did that with Cloudflare. AWS, we have extensions, Lambda extensions, et cetera, but we're doing it for more things. For Netlify, it's a one-click integration, too, and that's what we're trying to do to actually make the experience and the journey easier.Corey: I want to change gears a little bit because something that we spent a fair bit of time talking about—it's why we became friends, I would think anyway—is that we have a shared appreciation for several things. One of which, at most notable to anyone around us is whenever we hang out, we greet each other effusively and then immediately begin complaining about costs of cloud services. What is your take on the way that clouds charge for things? And I know it's a bit of a leading question, but it's core and foundational to how you think about Axiom, as well as how you serve customers.Seif: They're ripping us off. I'm sorry [laugh]. They just—the amount of money they make, like, it's crazy. I would love to know what margins they have. That's a big question I've always had. I'm like, what are the margins they have at AWS right now?Corey: Across the board, it's something around 30 to 40%, last time I looked at it.Seif: That's a lot, too.Corey: Well, that's also across the board of everything, to be clear. It is very clear that some services are subsidized by other services. As it should be. If you start charging me per IAM call, we're done.Seif: And also, I mean, the machine learning stuff. Like, they won't be doing that much on top of it right now, right, [else nobody 00:13:32] will be using it.Corey: But data transfer? Yeah, there's a significant upcharge on that. But I hear you. I would moderate it a bit. I don't think that I would say that it's necessarily an intentional ripoff. My problem with most cloud services that they offer is not usually that they're too expensive—though there are exceptions to that—but rather that the dimensions are unpredictable in advance. So, you run something for a while and see what it costs. From where I sit, if a customer uses your service and then at the end of usage is surprised by how much it cost them, you've kind of screwed up.Seif: Look, if they can make egress free—like, you saw how Cloudflare just did the egress of R2 free? Because I am still stuck with AWS because let's face it, for me, it is still my favorite cloud, right? Cloudflare is my next favorite because of all the features that are trying to develop and the pace they're picking, the pace they're trying to catch up with. But again, one of the biggest things I liked is R2, and R2 egress is free. Now, that's interesting, right?But I never saw anything coming back from S3 from AWS on S3 for that, like you know. I think Amazon is so comfortable because from a product perspective, they're simple, they have the tools, et cetera. And the UI is not the flashiest one, but you know what you're doing, right? The CLI is not the flashiest one, but you know what you're doing. It is so cool that they don't really need to compete with others yet.And I think they're still dominantly the biggest cloud out there. I think you know more than me about that, but [unintelligible 00:14:57], like, I think they are the biggest one right now in terms of data volume. Like, how many customers are using them, and even in terms of profiles of people using them, it's very, so much. I know, like, a lot of the Microsoft Azure people who are using it, are using it because they come from enterprise that have been always Microsoft… very Microsoft friendly. And eventually, Microsoft also came in Europe in these all these different weird ways. But I feel sometimes ripped off by AWS because I see Cloudflare trying to reduce the prices and AWS just looking, like, “Yeah, you're not a threat to us so we'll keep our prices as they are.”Corey: I have it on good authority from folks who know that there are reasons behind the economic structures of both of those companies based—in terms of the primary direction the traffic flows and the rest. But across the board, they've done such a poor job of articulating this that, frankly, I think the confusion is on them to clear up, not us.Seif: True. True. And the reason I picked R2 and S3 to compare there and not look at Workers and Lambdas because I look at it as R2 is S3 compatible from an API perspective, right? So, they're giving me something that I already use. Everything else I'm using, I'm using inside Amazon, so it's in a VPC, but just the idea. Let me dream. Let me dream that S3 egress will be free at some point.Corey: I can dream.Seif: That's like Christmas. It's better than Christmas.Corey: What I'm surprised about is how reasonable your pricing is in turn. You wind up charging on the basis of ingest, which is basically the only thing that really makes sense for how your company is structured. But it's predictable in advance, the free tier is, what, 500 gigs a month of ingestion, and before people think, “Oh, that doesn't sound like a lot,” I encourage you to just go back and think how much data that really is in the context of logs for any toy project. Like, “Well, our production environment spits out way more than that.” Yes, and by the word production that you just used, you probably shouldn't be using a free trial of anything as your critical path observability tooling. Become a customer, not a user. I'm a big believer in that philosophy, personally. For all of my toy projects that are ridiculous, this is ample.Seif: People always tend to overestimate how much logs they're going to be sending. Like so, there's one thing. What you said it right: people who already have something going on, they already know how much logs they'll be sending around. But then eventually they're sending too much, and that's why we're back here and they're talking to us. Like, “We want to ttry your tool, but you know, we'll be sending more than that.” So, if you don't like our pricing, go find something else because I think we are the cheapest out there right now. We're the competitive the cheapest out there right now.Corey: If there is one that is less expensive, I'm unaware of it.Seif: [laugh].Corey: And I've been looking, let's be clear. That's not just me saying, “Well, nothing has skittered across my desk.” No, no, no, I pay attention to this space.Seif: Hey, where's—Corey, we're friends. Loyalty.Corey: Exactly.Seif: If you find something, you tell me.Corey: Oh, if I find something, I'll tell everyone.Seif: Nononon, you tell me first and you tell me in a nice way so I can reduce the prices on my site [laugh].Corey: This is how we start a price was, industry-wide, and I would love to see it.Seif: [laugh]. But there's enough channels that we share at this point across different Slacks and messaging apps that you should be able to ping me if you find one. Also, get me the name of the CEO and the CTO while you're at it.Corey: And where they live. Yes, yes, of course. The dire implications will be awesome.Seif: That was you, not me. That was your suggestion.Corey: Exactly.Seif: I will not—[laugh].Corey: Before we turn into a bit of an old thud and blunder, let's talk about something else that I'm curious about here. You've been working on Axiom for something like seven years now. You come from a world of databases and events and the like. Why start a company in the model of Axiom? Even back then, when I looked around, my big problem with the entire observability space could never have been described as, “You know what we need? More companies that do exactly this.” What was it that you saw that made you say, “Yeah, we're going to start a company because that sounds easy.”Seif: So, I'll be very clear. Like, I'm not going to, like, sugarcoat this. We kind of got in a position where it [forced counterweighted 00:19:10]. And [laugh] by that I mean, we came from a company where we were dealing with logs. Like, we actually wrote an event crash analytics tool for a company, but then we ended up wanting to use stuff like Datadog, but we didn't have the budget for that because Datadog was killing us.So, we ended up hosting our own Elasticsearch. And Elasticsearch, it costs us more to maintain our Elasticsearch cluster for the logs than to actually maintain our own little infrastructure for the crash events when we were getting, like, 1 billion crashes a month at this point. So eventually, we just—that was the first burn. And then you had alert fatigue and then you had consolidating events and timestamps and whatnot. The whole thing just seemed very messy.So, we started off after some company got sold, we started off by saying, “Okay, let's go work on a new self-hosted version of the [unintelligible 00:20:05] where we do metrics and logs.” And then that didn't go as well as we thought it would, but we ended up—because from day one, we were working on cloud na—because we d—we cloud ho—we were self-hosted, so we wanted to keep costs low, we were working on and making it stateless and work against object store. And this is kind of how we started. We realized, oh, our cost, we can host this and make it scale, and won't cost us that much.So, we did that. And that started gaining more attention. But the reason we started this was we wanted to start a self-hosted version of Datadog that is not costly, and we ended up doing a Software as a Service. I mean, you can still come and self-hosted, but you'll have to pay money for it, like, proper money for that. But we do as a SaaS version of this and instead of trying to be a self-hosted Datadog, we are now trying to compete—or we are competing with Datadog.Corey: Is the technology that you've built this on top of actually that different from everything else out there, or is this effectively what you see in a lot of places: “Oh, yeah, we're just going to manage Elasticsearch for you because that's annoying.” Do you have anything that distinguishes you from, I guess, the rest of the field?Seif: Yeah. So, very just bluntly, like, I think Scuba was the first thing that started standing out, and then Honeycomb came into the scene and they start building something based on Scuba, the [unintelligible 00:21:23] principles of Scuba. Then one of the authors of actual Scuba reached out to me when I told him I'm trying to build something, and he's gave me some ideas, and I start building that. And from day one, I said, “Okay, everything in S3. All queries have to be serverless.”So, all the queries run on functions. There's no real disks. It's just all on S3 right now. And the biggest issue—achievement we got to lower our cost was to get rid of Kafka, and have—let's say, in behind the scenes we have our own coordination-free mechanism, but the idea is not to actually have to use Kafka at all and thus reduce the costs incredibly. In terms of technology, no, we don't use Elasticsearch.We wrote everything from the ground up, from scratch, even the query language. Like, we have our own query language that's based—modeled after Kusto—KQL by Microsoft—so everything we have is built from absolutely from the ground up. And no Elastic. I'm not using Elastic anymore. Elastic is a horror for me. Absolutely horror.Corey: People love the API, but no, I've never met anyone who likes managing Elasticsearch or OpenSearch, or whatever we're calling your particular flavor of it. It is a colossal pain, it is subject to significant trade-offs, regardless of how you work with it, and Amazon's managed offering doesn't make it better; it makes it worse in a bunch of ways.Seif: And the green status of Elasticsearch is a myth. You'll only see it once: the first time you start that cluster, that's what the Elasticsearch cluster is green. After that, it's just orange, or red. And you know what? I'm happy when it's orange. Elasticsearch kept me up for so long. And we had actually a very interesting situation where we had Elasticsearch running on Azure, on Windows machines, and I would have server [unintelligible 00:23:10]. And I'd have to log in and every day—you remember, what's it called—RP… RP Something. What was it called?Corey: RDP? Remote Desktop Protocol, or something else?Seif: Yeah, yeah. Where you have to log in, like, you actually have visual thing, and you have to go in and—Corey: Yep.Seif: And visually go in and say, “Please don't restart.” Every day, I'd have to do that. Please don't restart, please don't restart. And also a lot of weird issues, and also at that point, Azure would decide to disconnect the pod, wanted to try to bring in a new pod, and all these weird things were happening back then. So, eventually, end up with a [unintelligible 00:23:39] decision. I'm talking 2013, '14, so it was back in the day when Elasticsearch was very young. And so, that was just a bad start for me.Corey: I will say that Azure is the most cost-effective cloud because their security is so clown shoes, you can just run whatever you want in someone else's account and it's free to you. Problem solved.Seif: Don't tell people how we save costs, okay?Corey: [laugh]. I love that.Seif: [laugh]. Don't tell people how we do this. Like, Corey, come on [laugh], you're exposing me here. Let me tell you one thing, though. Elasticsearch is the reason I literally use a shock collar or a shock bracelet on myself every time it went down—which was almost every day, instead of having PagerDuty, like, ring my phone.And, you know, I'd wake up and my partner back then would wake up. I bought a Bluetooth collar off of Alibaba that would tase me every time I'd get a notification, regardless of the notification. So, some things are false alarm, but I got tased for at least two, three weeks before I gave up. Every night I'd wake up, like, to a full discharge.Corey: I would never hook myself up to a shocker tied to outages, even if I owned a company. There are pleasant ways to wake up, unpleasant ways to wake up, and even worse. So, you're getting shocked for some—so someone else can wind up effectively driving the future of the business. You're, more or less, the monkey that gets shocked awake to go ahead and fix the thing that just broke.Seif: [laugh]. Well, the fix to that was moving from Azure to AWS without telling anybody. That got us in a lot of trouble. Again, that wasn't my company.Corey: They didn't notice that you did this, or it caused a lot of trouble because suddenly nothing worked where they thought it would work?Seif: They—no, no, everything worked fine on AWS. That's how my love story began. But they didn't notice for, like, six months.Corey: That's kind of amazing.Seif: [laugh]. That was specta—we rewrote everything from C# to Node.js and moved everything away from Elasticsearch, started using Redshift, Redis and a—you name it. We went AWS all the way and they didn't even notice. We took the budget from another department to start filling that in.But we cut the costs from $100,000 down to, like, 40, and then eventually down to $30,000 a month.Corey: More than a little wild.Seif: Oh, God, yeah. Good times, good times. Next time, just ask me to tell you the full story about this. I can't go into details on this podcast. I'll get in a lot—I think I'll get in trouble. I didn't sign anything though.Corey: Those are the best stories. But no, I hear you. I absolutely hear you. Seif, I really want to thank you for taking the time to speak with me. If people want to learn more, where should they go?Seif: So, axiom.co—not dot com. Dot C-O. That's where they learn more about Axiom. And other than that, I think I have a Twitter somewhere. And if you know how to write my name, you'll—it's just one word and find me on Twitter.Corey: We will put that all in the [show notes 00:26:33]. Thank you so much for taking the time to speak with me. I really appreciate it.Seif: Dude, that was awesome. Thank you, man.Corey: Seif Lotfy, co-founder and CTO of Axiom, who has brought this promoted guest episode our way. I'm Cloud Economist Corey Quinn and this is Screaming in the Cloud. If you've enjoyed this podcast, please leave a five-star review on your podcast platform of choice, whereas if you've hated this podcast, please leave a five-star review on your podcast platform of choice, along with an angry comment that one of these days, I will get around to aggregating in some horrifying custom homebrew logging system, probably built on top of rsyslog.Corey: If your AWS bill keeps rising and your blood pressure is doing the same, then you need The Duckbill Group. We help companies fix their AWS bill by making it smaller and less horrifying. The Duckbill Group works for you, not AWS. We tailor recommendations to your business and we get to the point. Visit duckbillgroup.com to get started.
Commentary by Dr. Valentin Fuster
Welcome to the latest episode of Endpoints Shorts, presented by the ALS Therapy Development Institute. In these bite-size podcasts, we'll be tackling important scientific concepts for people interested in ALS research, current clinical trials, and news from around the ALS space – all in 15 minutes or less. Our guide throughout this series will be Dr. Nadia Sethi, ALS TDI's Director of Community Outreach and Engagement. Today, Nadia joins us to talk about PTC Therapeutics phase 2 trial for PTC 857. There are currently no treatments to stop or reverse ALS but the ALS Therapy Development Institute is working to change that. To learn more about ALS TDI and our research to end ALS, visit ALS.netSupport the show: https://www.als.net/donate/See omnystudio.com/listener for privacy information.
Andrea Lytle Peet's passion for running started simply enough. At age 30, she had just moved to Washington, D.C. to be with her husband, David. Stuck in their house during the snowy D.C. winter, she started walking on a treadmill in their basement to keep active. Soon, she had signed up for a local 5k. Then she stepped up to a 10 miler. Then came marathons and triathlons. Within three years, she had begun training for a half ironman. Then, at the age of 33, everything changed when she was diagnosed with ALS. In four months, she went from the strongest she had ever been to walking with a cane. However, this would not be the end of her athletic career. Despite having ALS for almost a decade, she is still able to ride a recumbent bike, which she has used to continue to participate in marathons all over the country. Recently, she reached a major milestone – completing at least one marathon in all 50 states. To commemorate this accomplishment and share her story to inspire others, Andrea is releasing two documents of her journey – a film, Go On, Be Brave and a memoir, Hope Fights Back. Today, on Endpoints, Andrea and David join us to talk about how she achieved these accomplishments in the face of such adversity, and why they believe it's important to share her story with the world.Support the show: https://www.als.net/donate/See omnystudio.com/listener for privacy information.
Dr. Jessica Ailani talks with Dr. Aaron Kesselheim and Leigh Sharpless about the endpoints used in trials supporting the US FDA approval of medications treating migraine. Read the related article in Neurology. This episode was sponsored by the ExTINGUISH Trial for NMDAR Encephalitis: Call 844-4BRAIN5 to refer patients.
Dr. Leigh Sharpless discusses her paper, "Variation in Endpoints in FDA Medication Approvals: A Review of Acute and Preventive Migraine Medications". Show References: https://n.neurology.org/content/101/10/e989 https://directory.libsyn.com/episode/index/id/27962343
In today's episode, Rachel Ford Hutman and I talk through her journey in media relations, starting Ford Hutman Media and thriving through brand awareness in the life sciences space. Rachel Ford Hutman is the Founder and CEO of Ford Hutman Media. With 15+ years of communications experience at leading global PR agencies and a senior comms role at IBM, she created the agency to provide industry-leading media relations and thought leadership to elite life science companies across the globe. Clients range from venture-backed startups to large cap public companies. Rachel started her career as a reporter and excels at working with the media to bring life science stories to life while still making them accessible to stakeholders.During her career, Rachel has led communications for the world's biggest therapies and medical technologies of all time, including the first RNAi therapy (Alnylam's ONPATTRO), the first technology in the world to personalize insulin 24 hrs. a day (Medtronic's MiniMed 670G), IBM's AI launch into healthcare (Watson Health), the first therapy for DMD (Sarepta's EXONDYS 51), and Google's sister life science company (Verily). She has counseled some of the most well-known health/ technology organizations and developed communications strategies for the world's biggest brands (Verily, Johnson & Johnson, Medtronic, Pfizer, IBM, Best Buy, Takeda, Sanofi, Shire, Brigham & Women's, NHS).Rachel is consistently leveraging her long-standing relationships with global agenda-setting reporters on behalf of clients including CNBC, FOX Business, BBC, AP, Reuters, Bloomberg, The Today Show, Newsweek, Financial Times, Fast Company, TIME, Wired, Forbes, WSJ, NYTs, and key health trades like Modern Healthcare, Becker's Hospital Review, Digital Health Journal, GenomeWeb, BioWorld, Tech Republic, FierceBiotech, Endpoints, Drug Discovery Today and many more. Rachel also has investor and analyst relations experience that adds to her ability to highlight market dynamics.Named a Power Woman of San Diego 2020 and PRSA's PR Professional of the Year in 2011, Rachel has built a reputation for her positive energy, creativity and humor. She received her MA in communications and media studies at San Diego State University and her BA in English/ History from University of Maryland, Baltimore County. Rachel has presented on communications strategy to PR News, PR Week, The International PR Research Conference, NC State and San Diego State University. You can find Rachel HERE More on Ford Hutman Media HERE Subscribe HERE for exclusive access and bonus episodes!This is an episode that you do not want to miss!Also, if you haven't already done so already, follow the podcast on LinkedIn HERE. I'm adding a bunch of bonus episodes to the feed and, if you're not following, there's a good chance you'll miss out.Join 1K+ women receiving my weekly newsletter where I help YOU level up your recruiting skills, share market insights also with all the tips on how to recruit your next Rockstar HERE Thanks for listening! Support the show
ALS TDI's ALS Research Collaborative (ARC) is a global initiative that partners with people with ALS to gather data about the disease to help us better understand the underlying biology of ALS and accelerate the discovery of treatments. Recently, ALS TDI announced a partnership with Unite Genomics, a healthcare data analytics company, that will allow us to integrate a new data source into the program – electronic health records (EHRs). Today, on Endpoints, we're joined by Unite Genomics CEO Taner Dagdelen, to tell us more about what this collaboration entails, what researchers can learn from EHR data, and what this means for present and future ARC participants. Support the show: https://www.als.net/donate/See omnystudio.com/listener for privacy information.
Welcome to the latest episode of Endpoints Shorts, presented by the ALS Therapy Development Institute. I'm Jonathan Gang. In these bite-size podcasts, we'll be tackling important scientific concepts for people interested in ALS research, current clinical trials, and news from around the ALS space – all in 15 minutes or less. Our guide throughout this series will be Dr. Nadia Sethi, ALS TDI's Director of Community Outreach and Engagement. Today, Nadia joins us to talk about Novartis Pharmaceuticals' phase 2 trial for BLZ945.Support the show: https://www.als.net/donate/See omnystudio.com/listener for privacy information.
Welcome to the latest episode of Endpoints Shorts, presented by the ALS Therapy Development Institute. In these bite-size podcasts, we'll be tackling important scientific concepts for people interested in ALS research, current clinical trials, and news from around the ALS space – all in 15 minutes or less. Our guide throughout this series will be Dr. Nadia Sethi, ALS TDI's Director of Community Outreach and Engagement. Today, Nadia joins us to talk about AL-S Pharma's phase 2 trial for AP-101. That there are currently no treatments to stop or reverse ALS but the ALS Therapy Development Institute is working to change that. To learn more about ALS TDI and our research to end ALS, visit als.net.Support the show: https://www.als.net/donate/See omnystudio.com/listener for privacy information.
Amazon SageMaker Multi-Model Endpoint (MME) is fully managed capability of SageMaker Inference that allows customers to deploy thousands of models on a single endpoint and save costs by sharing instances on which the endpoints run across all the models. Until recently, MME was only supported for machine learning (ML) models which run on CPU instances. Now, customers can use MME to deploy thousands of ML models on GPU based instances as well, and potentially save costs by 90%. MME dynamically loads and unloads models from GPU memory based on incoming traffic to the endpoint. Customers save cost with MME as the GPU instances are shared by thousands of models. Customers can run ML models from multiple ML frameworks including PyTorch, TensorFlow, XGBoost, and ONNX. Customers can get started by using the NVIDIA Triton™ Inference Server and deploy models on SageMaker's GPU instances in “multi-model“ mode. Once the MME is created, customers specify the ML model from which they want to obtain inference while invoking the endpoint. Multi Model Endpoints for GPU is available in all AWS regions where Amazon SageMaker is available. To learn more checkout: Our launch blog: https://go.aws/3NwtJyh Amazon SageMaker website: https://go.aws/44uCdNr
© 2020-2025 Ivy Podcast Discovery LLC
